Podcasts about jama health forum

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. There's been a lot of buzz lately about how GLP-1 weight-loss drugs like Ozempic and Wegovy are reshaping the food industry. With fewer people craving ultra-processed snacks, Big Food is scrambling to adapt—developing new products to regain lost sales. But can they really outsmart these medications? And what does this mean for your health?In this episode, we break down how the food industry is pivoting, what's at stake, and how you can take control—choosing where your money goes and what truly serves your health. Tune in for a deep dive into this shifting food landscape and what it means for you.ReferencesReciMe | The Ultimate Cooking AppDevotion NutritionA study published in JAMA Health Forum found that obesity prevalence and BMI decreased in the US in 2023, marking the first such decline in over a decadeThe Top 5 Mistakes People Make When Starting GLP-1 Audio Stamps01:00 - Dr. Rentea shares how the ReciMe app makes meal planning effortless and helps her find inspiration for easy, home-cooked meals.04:13 - Dr. Rentea breaks down how our obesogenic environment makes weight gain almost inevitable without intentional changes.07:29 - Ultra-processed foods override satiety, driving overeating by design. 12:14 - Aiming for 80% whole foods helps you better notice how ultra-processed foods affect your hunger and cravings.18:18 - Dr. Rentea shares how processed foods can be helpful in moderation, but whole foods should be the focus.21:40 - You get to decide where your money goes, whether it's supporting local farmers or prioritizing higher-quality, whole foods. It's about aligning your choices with your health and values.Quotes“We're in a modern world, but we have an ancient brain. And these foods are hyper palatable. It means that you want more of them than if you were to have naturally occurring food.”“In a climate where the companies do not care about you, you need to care about yourself.”“If about 80 percent of the time you're relying on whole based foods, you're able to tell more when you have that processed food, how it affects you.”“It's unrealistic, given that we're in a super hyper-processed environment, that you would never consume any of that.”“There is no universe where you're going to measure out a portion of chips and you're going to feel like you've had enough. It's not possible.”“You're not going to win All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Premium Season 1 of The Obesity Guide: Behind the Curtain -Dive into real clinical scenarios, from my personal medication journey to tackling weight loss plateaus, understanding insulin resistance, and overcoming challenges with GLP-1s. Plus, get a 40+ page guide packed with protein charts, weight loss formulas, and more. April 30/30 registration.

A recent study published in JAMA Health Forum suggests that institutions may be able to deploy custom open-source large language models (LLMs) that run locally without sacrificing data privacy or flexibility. Coauthors Thomas A. Buckley, BS, and Arjun K. Manrai, PhD, from the Department of Biomedical Informatics at Harvard Medical School join JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss. Related Content: Can Open-Source AI Models Diagnose Complex Cases as Well as GPT-4?

  You might have heard some misconceptions about Dual Eligible Special Needs Plans. In this episode we're busting those myths and highlighting D-SNPs' potential!   Read the text version   Contact the Agent Survival Guide Podcast! Email us ASGPodcast@Ritterim.com or call 1-717-562-7211 and leave a voicemail.   Resources: Agent's Guide to Digital Marketing Resources: https://lnk.to/D18qeY Building Client Loyalty: More than Just a Plan: https://ritterim.com/blog/building-client-loyalty-more-than-just-a-plan/ Changes to Medicare in 2025 Affect Dual Eligible Special Needs Plans: https://lnk.to/tj8oG1 Diversify Your Insurance Portfolio & Reap Real Rewards: https://ritterim.com/blog/diversify-your-insurance-portfolio-and-reap-real-rewards/ Get Your Insurance Portfolio Reviewed for FREE: https://ritterim.com/portfolio/ How Relationship Marketing Can Make the Difference in Your Agency: https://lnk.to/asg642 Register with Ritter Insurance Marketing: https://app.ritterim.com/public/registration/ The Beginner's Guide to D-SNPs: https://lnk.to/asg648   References: Freed, Salama, et al. “10 Things to Know about Medicare Advantage Dual-Eligible Special Needs Plans (D-Snps).” KFF, KFF, https://www.kff.org/medicare/issue-brief/10-things-to-know-about-medicare-advantage-dual-eligible-special-needs-plans-d-snps/. Accessed 31 Jan. 2025. Pena, Maria T., et al. “A Profile of Medicare-Medicaid Enrollees (Dual Eligibles).” KFF, KFF, 17 Feb. 2023, https://www.kff.org/medicare/issue-brief/a-profile-of-medicare-medicaid-enrollees-dual-eligibles/. “Beneficiaries Dually Eligible for Medicare & Medicaid.” CMS.Gov, Centers for Medicare & Medicaid Services, https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/downloads/medicare_beneficiaries_dual_eligibles_at_a_glance.pdf. Accessed 31 Jan. 2025. Biniek, Jeannie Fuglesten, et al. “Medicare Advantage in 2024: Enrollment Update and Key Trends.” KFF, KFF, 8 Aug. 2024, https://www.kff.org/medicare/issue-brief/medicare-advantage-in-2024-enrollment-update-and-key-trends/. Johnston, Kenton J., et al. “Nationwide Availability of and Enrollment in Medicare and Medicaid Dual-Eligible Special Needs Plans With Exclusively Aligned Enrollment.” Jama Network, Jama Health Forum, https://jamanetwork.com/journals/jama-health-forum/fullarticle/2824902. Accessed 31 Jan. 2025. “New Special Enrollment Periods (Seps) for Dually Eligible ...” CMS.Gov, Centers for Medicare & Medicaid, https://www.cms.gov/files/document/duals-lissepsjobaid01012025.pdf. Accessed 31 Jan. 2025. “Seniors & Medicare and Medicaid Enrollees.” Medicaid.Gov, https://www.medicaid.gov/medicaid/eligibility/seniors-medicare-and-medicaid-enrollees/index.html. Accessed 31 Jan. 2025.   Follow Us on Social! Ritter on Facebook, https://www.facebook.com/RitterIM Instagram, https://www.instagram.com/ritter.insurance.marketing/ LinkedIn, https://www.linkedin.com/company/ritter-insurance-marketing TikTok, https://www.tiktok.com/@ritterim X (fka) Twitter, https://twitter.com/RitterIM and Youtube, https://www.youtube.com/user/RitterInsurance    Sarah on LinkedIn, https://www.linkedin.com/in/sjrueppel/ Instagram, https://www.instagram.com/thesarahjrueppel/ and Threads, https://www.threads.net/@thesarahjrueppel  Tina on LinkedIn, https://www.linkedin.com/in/tina-lamoreux-6384b7199/   Not affiliated with or endorsed by Medicare or any government agency.

A study in NEJM shows that abelacimab, a fully human monoclonal antibody targeting factor XI, significantly reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients, suggesting a safer alternative for stroke prevention. Data from JAMA Health Forum reveals growing consolidation of primary care practices by hospitals and private equity firms, driving up healthcare costs without clear quality improvements. The largest U.S. tuberculosis outbreak in Kansas underscores the importance of vigilance and rapid response by healthcare providers, while a study in JAMA Network Open finds women, particularly nonmenopausal females aged 40–54, at higher risk for long COVID, emphasizing the need for tailored prevention and treatment strategies.

Incoming Editor in Chief Sandro Galea, MD, DrPH, discusses the journal and the state of health policy with Deputy Editor Julie Donohue, PhD, and Senior Editor Melinda Buntin, PhD. Related Content: JAMA Health Forum: Meet the Editor in Chief, Sandro Galea, MD, DrPH JAMA Health Forum—Paving the Way for the Future of Health Policy Science and Scholarship

Founding Editor in Chief John Ayanian, MD, MPP, reflects on the origins and the highlights of the journal's first 5 years, including seminal publications, the journal's current No. 1 slot in the rankings, and the amazingly collegial editorial team, with JAMA Health Forum founding Deputy Editor Melinda Buntin, PhD. Related Content: Reflections on the First 5 Years of JAMA Health Forum

AcademyHealth CEO Aaron Carroll, MD, MS, shares highlights from the AcademyHealth 2024 Annual Research Meeting in an interview hosted by JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD. John and Melinda then discuss key findings from 4 highly rated abstracts presented at the meeting that were published concurrently as Original Investigations in JAMA Health Forum. Related Content: Coverage and Access Changes During Medicaid Unwinding Changes in Health Care and Prescription Medication Affordability in the US During the COVID-19 Pandemic Household Health Care Payments Under Rate Setting, Spending Growth Target, and Single-Payer Policies Pay-for-Performance Incentives for Home Dialysis Use and Kidney Transplant JAMA Health Forum Highlights From the AcademyHealth Annual Research Meeting

Today we are revisiting a conversation from Season 6 Episode 2 with Adam Beckman, former Special Advisor to the US Surgeon General. He and Dr. David Chokshi, former New York City Health Commissioner, called on hospitals to end five administrative practices that harm patients in their October 2022 article in JAMA Health Forum. In our conversation, we dove deep into that article, and talked about ways individuals can get engaged. JAMA article: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2798115 To support the podcast: https://www.fixmoralinjury.org/get-started Twitter - @fixmoralinjury Instagram - @moralinjury Facebook - @moralinjuryofhc

A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research,… Source

We hear it all the time: We are experiencing a mental health crisis. In recent years, the use of mental health services jumped by nearly 40% among millions of commercially insured and American adults, according to a recent JAMA Health Forum. Today we're starting a yearlong series of monthly conversations about mental health with Nieisha Deed, founder of the organization PureSpark. Her affirmation for us: "I trust myself." Want more? Visit gbhnews.org/wakeupwell.

Five U.S. cities implemented a tax on sugar-sweetened beverages between 2017 and 2018, as a key policy to reduce cardiometabolic diseases and other health conditions. Did consumers reduce their consumption? Listen in this week as Dee discusses the results of a recent study that examined the correlation between increases in prices of sugar-sweetened beverages and purchases.Reference:Kaplan, S., White, J. S., Madsen, K. A., Basu, S., Villas-Boas, S. B., & Schillinger, D. (2024). Evaluation of changes in prices and purchases following implementation of sugar-sweetened beverage taxes across the US. JAMA Health Forum, 5(1), e234737. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2813506

This week we (@ajhollingsworth) talk with Andrew Friedson on how to get a book published. Andrew is a research director at the Milken Institute. Previously he was an associate professor on economics at UC Denver. He recently has published his first book "Economics of Healthcare" is out now! This textbook is an introduction to health economics to people without much of the Econ-background. Get the book here P.S. We've are back! Share any episode on your favorite social media and send us a receipt at hiddencurriculumpodcast@gmail.com or just by doing it on twitter we will notice it! Sebastian Tello-Trillo is an Assistant Professor of Public Policy and Economics at the Frank Batten School of Leadership and Public Policy in the University of Virginia. Alex Hollingsworth is an Associate Professor of at the Ohio State University Andrew Friedson, PhD, is the director of health economics in the Milken Institute's Research Department. He heads projects concerning health, health care, and related sectors. Prior to joining the Milken Institute, he spent over a decade in academia where he was an associate professor of economics at the University of Colorado, Denver, with a secondary appointment in the department of health systems management and policy at the Colorado School of Public Health.  He has wide expertise in health economics and has published peer-reviewed research on health behaviors, markets, and policy in premiere journals in economics, public policy, and medicine including the Journal of Public Economics, the Journal of Law and Economics, and JAMA Health Forum. Friedson received the Richard Musgrave Prize from the National Tax Association in 2014. His textbook, Economics of Healthcare: A Brief Introduction will be released soon by Cambridge University Press. Friedson received a PhD and a MA in Economics from Syracuse University and BAs in Economics and Mathematics from the University of Rochester. --- Send in a voice message: https://podcasters.spotify.com/pod/show/hidden-curriculum/message

In episode 35 we discuss whether eliminating prior auths leads to more buprenorphine prescribing. Christine PJ, Larochelle MR, Lin L, McBride J, Tipirneni R. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder. JAMA Health Forum. 2023;4(10):e233549. We also discuss buprenorphine diversion, and the lack of treatments for stimulant use disorder. Harm Reduction Journal: Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study NBC news: Why are there no treatments for cocaine and meth addiction?  ---------- This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, please visit MI CARES. ---------- Episode 35 Credits: Original theme music: composed and performed by Benjamin Kennedy Audio production: Erin McCue Executive Producer: Dr. Patrick Beeman A podcast from Ars Longa Media ---------- This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.  The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group. Email: addictionmedicinejournalclub@gmail.com  Facebook: @AddictionMedJC Facebook Group: Addiction Medicine Journal Club Instagram: @AddictionMedJC  Threads: @AddictionMedJC Twitter/X: @AddictionMedJC  YouTube: addictionmedicinejournalclub Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

A cognitive neuroscientist by training, Dr. Vijeth Iyengar ( https://www.aarpinternational.org/about-us/staff/vijeth-iyengar ) is Director of Global Aging at AARP where he leads cutting-edge research, drives thought leadership on global aging issues, and cultivates relationships and strategic alliances to promote the enterprises vision for the global 50+ population.Prior to joining AARP, Dr. Iyengar served in a variety of roles in the U.S. Federal Government including as Brain Health Lead and Technical Advisor to the Deputy Assistant Secretary for Aging, as a Policy Advisor to the 4th Chief Technology Officer at the White House Office of Science and Technology Policy, as co-lead coordinator of the older adult working group for the Healthy People 2020/2030 initiative, and as lead author of the U.S. Country Report for the Fourth Review and Appraisal of the Madrid International Plan of Action on Ageing – a process overseen by the United Nations Economic Commission for Europe.Among other recognitions, Dr. Iyengar was a National Science Foundation Graduate Research Fellow, a Presidential Management Fellow, selected as a Aspen Ideas Festival Health Fellow, and a Bronze Telly Award Winner for work on AARP's Aging Readiness & Competitiveness Initiative. He has contributed articles appearing in Devex, JAMA Health Forum, Scientific American, STAT News, National Academy of Medicine Perspectives, and WHO Bulletin.Dr. Iyengar serves as a Nonresident Senior Fellow at the Atlantic Council, an Advisor to Ashoka's New Longevity Initiative, Member of the SUNY-Albany Healthy Aging Initiative Community Advisory Committee, Regional Mentor for the Atlantic Fellows Equity in Brain Health Program, Mentor for the Techstars Future of Longevity Accelerator, and Principal Member of the Meridian International Center Corporate Council.A native of Louisiana, he was a visiting undergraduate student at Cornell University, received his bachelor's degree from Tulane University and masters and doctoral degrees from Duke University.Support the show

For a full transcript of this episode, click here. This show is a very natural follow-on to episode 418 with Mark Cuban and Ferrin Williams, PharmD, MBA. This show is the how, as in, “How did everything that we talked about in the earlier show wind up the way it did?” And it also proves it … with data. I gotta say I never quite understood the finer points of the rationale of a cash pay system for minor expenses—expenses like generic drugs. I always framed this whole thing in the context of a senior on a fixed income taking 10 drugs, as my grandma did. And even if each of those drugs was only $5 or $10 a month, that's enough beans a month that it was a big deal for her to swing. So, I have always had this thought that these drugs should be covered by her insurance so she and everybody else living on a fixed income trying to make ends meet could get them and take them and not die from complications of diabetes or high blood pressure. Now, the counterargument to the above, which I have certainly heard more than once, is to offer members/patients HSAs (health savings accounts) and have them buy stuff with their HSA. My knee jerk there is, yeah, but I can barely figure out the deal with HSAs. Most Americans don't even know what a deductible is let alone an HSA. This approach just feels like it demands a lot of health literacy. So, that's the place I was when I walked into this conversation in this episode with Ge Bai, PhD, CPA. Here's two facts that got me inching away from my original position: 1. Generic drugs are cheap. There is already competition in the manufacturing marketplace that holds these prices down. 2. PBMs (pharmacy benefit managers) and insurance are devices to pool risk. If you have a high expense, that expense gets spread out over the rest of the insured population (ie, the risk pool). This whole spreading out of the risk is arduous to pull off and requires a level of administrative costs. So, let's break this down: In terms of #1 fact, that generic drugs are cheap, let's think about the value prop of PBMs. It's to throw their market power around to lower drug prices. But, oh wait … the prices of cheap generics are already cheap. So, not much need for market power? Yeah, that's a fact. One of the studies that I talk about in this healthcare podcast with Ge Bai quantifies that. For patients in their deductible phase actually, 79% of the time paying cash is cheaper than if the patient had used their insurance and gotten the price “negotiated by their PBM.” So, yeah … anytime pretty much anybody can wander in and get a better price than a Fortune 15 PBM, it's pretty clear that market power is not overly required here. In fact, getting PBMs in the mix just seems to make the drug prices higher for patients. Alright now, moving on to my fact #2 I talked about earlier, which is, what is the point of insurance (and PBMs are a derivative of insurance)? The point with them is to pool risk, to spread out the cost of something over the entire risk pool. So, yeah … drug costs $3. What is the administrative burden that goes in to spreading $3 across a risk pool? Is it worth it? Or is the admin cost burden more burdensome than the actual cost burden of the cost of the drug, and all we're doing here is driving up the price of healthcare, which ultimately might throw more financial burden back on the patient through higher premiums or out-of-pockets? That's the second study that I talk about today with Ge Bai, and it quantifies exactly how much that administrative burden is when it comes to generic drugs. Because you know who makes the most money in a generic drug transaction? No, it's not the pharma manufacturer, if that's what you were thinking. It's not the pharmacy. It's not the wholesaler. Yeah, it's the PBM. The PBM, by a margin of 10 points, makes the most money. The administrative cost burden is actually the most expensive part of buying a generic drug using your insurance and going through that PBM. There's a bar chart that visualizes these proportions. But while I'm on a roll here, here's a #3 fact that speaks to my concerns about HSAs that I raised at the beginning and the financial literacy required to use them: Health insurance is already super complicated, and no one can understand it. And here's a #4 let's-talk-about-the-real-world fact: Health insurance and paying for drugs is already pretty unaffordable for lots of people. So, I guess in theory it would be amazing if we could have our drugs paid for so they could be affordable. And if that were true and things were a little complicated … okay, trade-offs and all that. But right now, the situation is that drugs can be pretty unaffordable, including “cheap” generics; AND getting them covered is complicated. So, bar is pretty low to do better by patients is my point. And this is what I talk about with, as aforementioned, my guest today, Ge Bai. Ge Bai probably needs no introduction. She is a professor of accounting at Johns Hopkins Carey Business School and also a professor of health policy and management at Johns Hopkins Bloomberg School of Public Health. As she says, she studies nothing but healthcare dollars. Also mentioned in this episode is the show with Steven Quimby, MD (EP344) going deep on the generic drug market. Additional links for this episode: Links for second study: JAMA Health Forum, coauthored with Joey Mattingly, Kenechukwu Ben-Umeh, Gerard Anderson; The Johns Hopkins University - Carey Business School; Johns Hopkins Bloomberg School of Public Health; University of Utah College of Pharmacy Bar chart/article: by Jason Shafrin You can learn more about Ge's research on LinkedIn and X (formerly Twitter).   Ge Bai, PhD, CPA, is a professor of accounting at the Johns Hopkins Carey Business School and professor of health policy and management at the Johns Hopkins Bloomberg School of Public Health. An expert on healthcare accounting, finance, and policy, she has testified in Congress, written for the Wall Street Journal and the Washington Post, and published her studies in leading academic journals such as the New England Journal of Medicine, JAMA, and Health Affairs. Her work has been widely featured in the media and cited in regulations and congressional testimonies. She was a visiting scholar at the Health Analysis Division of the Congressional Budget Office from 2022 to 2023. She teaches graduate courses and has received the Johns Hopkins Alumni Association's Excellence in Teaching Award.   06:13 What is the background on generic drugs that is need-to-know? 06:39 EP344 with Steven Quimby, MD. 07:04 Do we have affordability for generic drugs? 15:40 What's the policy failure around generic drugs? 18:34 Why is there a huge health equity issue? 20:13 How do PBMs have both a monopoly and a monopsony? 21:59 What should be the goal for cheap generics? 23:36 “Whenever we have no competition, we'll see high price.” 26:00 What's the best approach to addressing operational challenges behind generic drug costs? 28:42 How do we solve generic drug costs on the back end? 31:15 “Healthcare insurance is not the same as health.” 36:07 “It's time for us to reflect and think whether there is a better way to try.”   You can learn more about Ge's research on LinkedIn and X (formerly Twitter).   @GeBaiDC discusses paying cash for #genericdrugs in our #healthcarepodcast. #healthcare #podcast #digitalhealth   Recent past interviews: Click a guest's name for their latest RHV episode! Andreas Mang, Karen Root (Encore! EP381), Mark Cuban and Ferrin Williams, Dan Mendelson (Encore! EP385), Josh Berlin, Dr Adam Brown, Rob Andrews, Justina Lehman, Dr Will Shrank, Dr Carly Eckert (Encore! EP361)

In this episode of the Better Edge podcast, Sadiya S. Khan, MD, MSc, the Magerstadt Professor of Cardiovascular Epidemiology and associate professor of Cardiology and Preventive Medicine at Northwestern Medicine, discusses her research on the associations between neighborhood-level racial residential segregation, socioeconomic factors and life expectancy in the US. Dr. Khan explains how social determinants of health contribute to disparities in life expectancy and recommends how physicians can improve health equity in their own practice. JAMA Health Forum.2023;4(7):e231805.

Christianity and Culture: Is Therapy Doing More Harm Than Good? Therapy seems to be all the rage. JAMA Health Forum recently reported use of mental health services has jumped by almost 40% and for most young people today believe therapy is normal and everyone should be in it. Why then are we seeing a mental health crisis exploding across our nation and in the western world, especially among young people? And what's the difference between secular therapy and Christian therapy? In this discussion, Lenny talks with Dr. Jacob Daniel and Tom Thomazin, a Christian counselor with over thirty years of experience to flesh out both the benefits and the limitations of our modern therapeutic mindset.

In this episode of “The Top Line,” we delve into the FDA's controversial approval of Aduhelm, a drug for Alzheimer's disease, despite an independent advisory committee's resounding rejection. The decision has sparked questions about potential bias within the regulatory body.   Genevieve Kanter, Ph.D., a professor at the USC Sol Price School of Public Policy, joins Fierce's Kevin Dunleavy to discuss the implications of a study published in July in JAMA Health Forum, which found the FDA's propensity to favor positive panel recommendations. They explore the impact of this potential bias on drug development and public health. See omnystudio.com/listener for privacy information.

Brain Health Coach and Consultant Leigh Richardson joins Dawn to respond to the latest reports from Axios on Mental Health. Her initial focus was on organizational behavior. She shifted to human behavior in 2003 after her son suffered a traumatic brain injury. Leigh has also been in ICU twice with brain injury. All of this fueled her need to understand how the brain works or why it doesn't work. REPORT: (Axios)A trio of new studies paints a grim picture of how overdose deaths, depression and barriers to care are... aligning to widen health disparities as the U.S. emerges from the pandemic...Overdose deaths What they found: Educational attainment was a huge factor in who might die from an overdose from 2000 to 2021, with differences becoming especially stark during the pandemic, a study published last week in JAMA Health Forum found. From 2019 to 2021, the overdose death rate for people who didn't attend college at all increased by 30.6 per 100,000 people, the study found. In contrast, the death rate for people with at least some college increased by only 4.5 per 100,000..."The opioid crisis has increasingly become a crisis disproportionately impacting those without any college education," the study concludes.Teens with depression What they found: In 2021, 1 in 5 adolescents had major depressive disorder, but less than half who needed treatment received any, per a study published this week in JAMA Pediatrics. Teenagers of color — particularly Latinos — had the lowest treatment rates... Adult depression and mortalityWhat they found: Adults with depression — particularly moderate or severe cases — are at higher risk of dying from cardiovascular disease, ischemic heart disease and other causes, according to a new study in JAMA Network Open... In 2020, some 21 million U.S. adults (8.4%) had at least one major depressive episode. Researchers noted the onset of cardiovascular disease occurs an average of 7.5 years earlier in adults with mood disorders. Read more.What is driving these spikes in depression and overdose deaths? And what can each of us do to help a loved one who may be struggling with these issues? Tune in 10 AM - 12 PM EST weekdays on Talk Radio 1210 WPHT; or on the Audacy app!

Leigh Richardson, Licensed Professional Counselor and Founder at the Brain Performance Center in Dallas, TX joins Dawn to expand on the trends around mental health and therapy in 2023. Leigh expands on the willingness to turn to therapy, and the different levels to it as Americans come to terms with their mental state. Leigh reacts to the latest reports from Time Magazine - By the latest federal estimates, about one in eight U.S. adults now takes an antidepressant and one in five has recently received some kind of mental-health care, an increase of almost 15 million people in treatment since 2002. Even in the recent past—from 2019 to 2022—use of mental-health services jumped by almost 40% among millions of U.S. adults with commercial insurance, according to a recent study in JAMA Health Forum. Tune in 10 AM - 12 PM EST weekdays on Talk Radio 1210 WPHT; or on the Audacy app!  

JAMA Health Forum Editor John Ayanian, MD, and Deputy Editor Melinda Buntin, PhD, discuss with Sandra B. Nelson, MD (Massachusetts General Hospital, Boston), her JAMA Health Forum study of transmission of SARS-CoV-2 in schools in Massachusetts during 2 different phases of the COVID-19 pandemic. She found transmission rates were very low but varied by district and the availability of vaccines. Related Content: Prevalence and Risk Factors for School-Associated Transmission of SARS-CoV-2

JAMA Health Forum Editor John Ayanian, MD, and Deputy Editor Melinda Buntin, PhD, discuss with Sandra B. Nelson, MD (Massachusetts General Hospital, Boston), her JAMA Health Forum study of transmission of SARS-CoV-2 in schools in Massachusetts during 2 different phases of the COVID-19 pandemic. She found transmission rates were very low but varied by district and the availability of vaccines. Related Content: Prevalence and Risk Factors for School-Associated Transmission of SARS-CoV-2

In November of 2022, Ava Kofman published a piece in the New Yorker titled “How Hospice Became a For-Profit Hustle.”  Some viewed this piece as an affront to the amazing work hospice does for those approaching the end of their lives by cherry picking stories of a few bad actors to paint hospice is a bad light. For others, this piece, while painful to read, gave voice to what they have been feeling over the last decade - hospice has in some ways lost its way in a quest of promoting profit over care. On today's podcast, live from the American Academy of Hospice and Palliative Medicine Annual Meeting, we invite two thought leaders in the field, Ira Byock and Joseph Shega, to discuss among other things: Is hospice losing its way? Is there a difference between for-profit and not-for-profit when it comes to quality of care? What is our role as hospice and palliative care providers in advocating for high-quality hospice care? If you are interested in signing the position statement “Core Roles and Responsibilities of Physicians in Hospice Care”, click here. For a deeper diver into these issues, check out some of the following links:     Ira's Stat new article “Hospice care needs saving” GeriPal's episode on the growing role of private equity in hospice care Acquisitions of Hospice Agencies by Private Equity Firms and Publicly Traded Corporations. JAMA IM 2021 Hospice Acquisitions by Profit-Driven Private Equity Firms. JAMA Health Forum. 2021 Association of Hospice Profit Status With Family Caregivers' Reported Care Experiences.  JAMA IM 2023 A shout-out to my NPR episode on 1A titled the “State of Hospice Care”   DISCLAIMER While we filmed in Montreal during the Annual Assembly, all opinions expressed in this podcast are independent of AAHPM and HPNA, or the Annual Assembly.  Furthermore, direction to external websites is not an endorsement from AAHPM or HPNA, or the Annual Assembly.    ---------------------------  

Adam Beckman, former Special Advisor to the US Surgeon General, and Dr. David Chokshi, former New York City Health Commissioner, called on hospitals to end five administrative practices that harm patients, in their October 2022 article in JAMA Health Forum. We dove deep into that article, and talked about ways individuals can get engaged. JAMA article: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2798115 To support the podcast: https://www.fixmoralinjury.org/get-started Twitter - @fixmoralinjury Instagram - @moralinjury Facebook - @moralinjuryofhc LinkedIn - @moral Injury of Healthcare  

A discussion of vaccine information, hesitancy and uptake among multiple populations and how we can improve uptake in our daily practices Show References McElfish PA, Willis DE, Shah SK, Bryant-Moore K, Rojo MO, Selig JP. Sociodemographic Determinants of COVID-19 Vaccine Hesitancy, Fear of Infection, and Protection Self-Efficacy. J Prim Care Community Health. Jan-Dec 2021;12:21501327211040746. doi:10.1177/21501327211040746  MacDonald NE, Hesitancy SWGoV. Vaccine hesitancy: Definition, scope and determinants. Vaccine. Aug 14 2015;33(34):4161-4. doi:10.1016/j.vaccine.2015.04.036  Nguyen LH, Joshi AD, Drew DA, et al. Racial and ethnic differences in COVID-19 vaccine hesitancy and uptake. medRxiv. Feb 28 2021;doi:10.1101/2021.02.25.21252402  Wong LP, Alias H, Danaee M, et al. COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries. Infect Dis Poverty. Oct 7 2021;10(1):122. doi:10.1186/s40249-021-00900-w  Jacobson RM, St Sauver JL, Finney Rutten LJ. Vaccine Hesitancy. Mayo Clin Proc. Nov 2015;90(11):1562-8. doi:10.1016/j.mayocp.2015.09.006  S. B. Omer, D. A. Salmon, W. A. Orenstein, M. P. deHart and N. Halsey. Vaccine Refusal, Mandatory Immunization, and the Risks of Vaccine-Preventable Diseases. NEJM 2009 Vol. 360 Issue 19 Pages 1981-1988  Lila J. Finney Rutten, Xuan Zhu, Aaron L. Leppin, Jennifer L. Ridgeway, Melanie D. Swift, Joan M. Griffin, Jennifer L. St Sauver, Abinash Virk, Robert M. Jacobson. Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy. Mayo Clinic Proceedings. Volume 96, Issue 3. 2021. Pages 699-707.  Raymond John D Vergara, Philip Joseph D Sarmiento, James Darwin N Lagman, Building public trust: a response to COVID-19 vaccine hesitancy predicament, Journal of Public Health, Volume 43, Issue 2, June 2021, Pages e291–e292, https://doi.org/10.1093/pubmed/fdaa282  Corbie-Smith G. Vaccine Hesitancy Is a Scapegoat for Structural Racism. JAMA Health Forum. 2021;2(3):e210434. doi:10.1001/jamahealthforum.2021.0434 The 'successful failures' of Apollo 13 and Covid-19 vaccination - STAT (statnews.com)

The CyberPHIx Roundup is your quick source for keeping up with the latest cybersecurity news, trends, and industry-leading practices, specifically for the healthcare industry.  In this episode, our host Britton Burton highlights the following topics trending in healthcare cybersecurity this month:  New FDA authority granted by December's omnibus bill is a big step towards better medical device security  HITRUST teases their new CSF v11 release  CommonSpirit Health class action lawsuit  The fallout from the LastPass follow-on breach  The possibly similar situation that might be occurring at Okta   JAMA Health Forum's outstanding metrics study on ransomware attacks in healthcare from 2016 – 2021  The nefarious use cases of OpenAI's ChatGPT  Clop ransomware group's tactics for taking advantage of Telehealth appointments to deploy malware  An apology from LockBit ransomware group for an attack on a children's hospital (really!)  Healthcare CISOs collaborating thru Healthe3PT to solve the third-party risk problem  A major precedent-setting breach settlement order from FTC against Drizly and its CEO     

In this episode we'll speak with Dr. Julie Bynum who was the senior author on a recent study that examined how the likelihood of receiving a diagnosis of dementia has changed over the last decade or so. We'll discuss what this might mean clinically and what researchers that rely on Medicare data should take-away from this finding. We also will talk in general about the various approaches that exist for identification of dementia in Medicare billing data. Julie Bynum Faculty Profile: https://medicine.umich.edu/dept/dgpm/julie-bynum-md-mph Article Referenced in this Episode Davis MA, Chang CH, Simonton S, Bynum JPW. Trends in US Medicare Decedents' Diagnosis of Dementia From 2004 to 2017. JAMA Health Forum. 2022 Apr 1;3(4):e220346. doi: 10.1001/jamahealthforum.2022.0346. PMID: 35977316 Resources: The Bynum-Standard 1-Year Algorithm for identifying Alzheimer's Disease and Related Dementias (ADRD) in Medicare Claims data. The transcript for this episode can be found here.CAPRA Website: http://capra.med.umich.edu/ You can subscribe to Minding Memory on Apple Podcasts, Spotify, Google Podcasts or wherever you listen to podcasts. Hosted on Acast. See acast.com/privacy for more information.

Thanks to members of Phi Delta Chi's Delta Beta Chapter for creating this episode - Angelica Okinda, Nihitha Nukala, Shannyn Gilchrist-Oates, Hunter Kieltyka, Sydney Thompson, Dylan J. McNutt, Kristopher S. Ingram, Rebecca Nelson, and Emmanuel Rodivera! This week on Pharm5: Glaspie v. NABP Chlorthalidone not superior to HCTZ Krazati (adagrasib) FDA approval ASHP reports 20 states prescribing OCP Federal COVID-19 vaccine funding ends Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Ludens ZD, Glaspie E. In the United States District Court for the Northern District of Illinois. Class Action. https://bit.ly/3V7VhM5. Published November 19, 2022. Accessed December 15, 2022. @NABP. As you may have heard, 220 candidates who took the NAPLEX between July 30th and October 26th received incorrect exam results. https://bit.ly/3UXHfN3. Posted November 10, 2022. Accessed December 15, 2022. Ishani A, Leatherman SM, Woods P, et al. Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's diuretic comparison project. Contemporary Clinical Trials. 2022;116:106754. doi:10.1016/j.cct.2022.106754 Flack JM, Sica DA, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic. Hypertension. 2011;57(4):665-666. doi:10.1161/hypertensionaha.110.164566 Ishani A, Cushman WC, Leatherman SM, Lew RA, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events. 10.1056/NEJMoa2212270. FDA grants accelerated approval to Adagrasib for Kras-G12C-mutated NSCLC. Pharmacy Times. https://bit.ly/3YvCRI8. Published December 13, 2022. Accessed December 15, 2022. Pharmacists can now prescribe hormonal birth control in 20 states. https://bit.ly/3HGMYUI. Published December 5, 2022. Accessed December 15, 2022. Contraception. Centers for Disease Control and Prevention. https://bit.ly/3BGTRl7. Published November 1, 2022. Accessed December 15, 2022. Pharmacist prescribing: Hormonal contraceptives. https://bit.ly/3hqbHSx. Published December 6, 2022. Accessed December 15, 2022. Stephenson J. US COVID-19 Vaccine Costs Expected to Soar if Funding for Federal Program Ends. JAMA Health Forum. 2022;3(12):e225376. doi:10.1001/jamahealthforum.2022.5376 Artiga S, Tolbert J, Kates J, Rudowitz R. Implications of the lapse in federal covid-19 funding on access to covid-19 testing, treatment, and vaccines. KFF. bit.ly/3FWDLpM. Published March 28, 2022. Accessed December 15, 2022.

Private equity firms typically buy privately owned companies and restructure them to maximize profits for investors. Private equity has been expanding its presence in the healthcare industry in recent years, with firms buying up hospitals, nursing homes, medical practices, ambulance providers and companies specializing in medical debt collection. A new study examines how both healthcare spending and patient visits changed among private equity-acquired medical practices compared to independently owned medical practices from 2016 to 2020. The researchers found that private equity-acquired medical practices charged 20 percent more, on average, per insurance claim, and saw a nearly 40% increase in new patients compared to independently owned practices. Joining us now is Jane Zhu, a primary care physician and an assistant professor of medicine at Oregon Health & Science University, who co-authored the study published in JAMA Health Forum.

 Listen, sometimes the summer just gets away from you and people start to be concerned that you've either quit your cancer podcast or died. If that's you, no judgment. Amy and Stef, however, would NEVER abandon their loyal listeners for two months to live their best parasol-twirling, innertubing, redwood hugging, concert-in-the-parking, WNBA gaming (go Storm!!) lives. Salad days, amirite? (Seriously, am I?) So…anyway…the gals are back with new scan results and some dirt to dish. Stef's kids are bunking at Camp Kesem (kesem.org), communing with nature and other children of cancer people. It's free! It's fantastic! We stan! Amy's prepping for fat grafting surgery, but rest assured, her boobs will always turn heads at Trader Joe's. Then, fertility feelings: we've (almost) all got ‘em. We'd love to hear from you, pals, but until then, consider: do our triggers need to take center stage? (….don't say “stage”!) Finally, we take on the ‘warrior' problem, for the honor of ONJ. Maybe some script-flipping is in order! In any case, it's all up…or down…hill from here! Birthday babe Jessica Boudreaux (Summer Cannibals) new album here. Empowered Mastectomy is here.RATS: The WCRF article is hereComparison of Cancer-Related Spending and Mortality Rates in the US the best vs 21 High-Income Countries” by Ryan D. Chow, Ph.D., Elizabeth H. Bradley, Ph.D. and Cary P. Gross, MD, 27 May 2022, JAMA Health Forum. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2792761https://scitechdaily.com/the-us-spends-200-billion-each-year-on-cancer-care-we-might-not-be-getting-our-moneys-worth/

Rishi K. Wadhera, MD, MPP, MPhil, Beth Israel Deaconess Medical Center, discusses his article investigating the association of the Medicare Hospital Value-Based Purchasing program with changes in patient care experience at safety-net vs non–safety-net hospitals with JAMA Health Forum editors John Z. Ayanian, MD, MPP, and Melinda B. Buntin, PhD. Related Content: Association of the Medicare Value-Based Purchasing Program With Changes in Patient Care Experience at Safety-net vs Non–Safety-net Hospitals

A prune—or six—a day may keep inflammation at bay   Pennsylvania State University, April 1, 2022   A study in postmenopausal people suggests eating nutrient-rich prunes every day may be beneficial to bone health, reducing inflammatory factors that contribute to osteoporosis. Previous research has shown that polyphenol extracts—plant compounds that act as antioxidants and reduce inflammation—in prunes promote lower levels of oxidative stress and inflammation in a type of bone cell called osteoclasts. In a new study, researchers explored the effects of prunes on bone health after menopause. Postmenopausal women with a bone mineral density score that was defined as low—a marker of osteoporosis—were divided into three groups: One group ate 50 grams (g) of prunes (about six prunes) daily for 12 months. A second group ate 100 g of prunes (about 12 prunes) daily for 12 months. A control group ate no prunes.   (NEXT)   Cardamonin shows promise for treating aggressive breast cancer   Study shows that compound from cardamom spice can kill triple-negative breast cancer cells    Florida A&M University, April 3, 2022   Cardamonin — a natural compound found in the spice cardamom and other plants — could have therapeutic potential for triple-negative breast cancer, according to a new study using human cancer cells. The findings also show that the compound targets a gene that helps cancer cells elude the immune system. About 10-15% of breast cancers are triple-negative, which means they don't have receptors for estrogen or progesterone and don't make excess amounts of a protein called HER2. These tumors are difficult to treat because they don't respond to the hormone-based therapies used for other types of breast cancer. They also tend to be more aggressive and have a higher mortality rate than other breast cancers.   (NEXT)   Mineral supplement could stop fatty liver disease progression   University of Michiganm April 3, 2022   Results from a preclinical study add new evidence that a multi-mineral dietary supplement known as Aquamin could be a simple and effective way to reduce the long-term health consequences of non-alcoholic fatty liver disease. Aquamin, which is derived from calcified red marine algae, is rich in calcium, magnesium and 72 other minerals and trace elements. Most people living in Western society do not meet the USDA daily intake guidelines for the intake of calcium and magnesium and, presumably, other minerals nutritionally associated with these minerals. In preliminary studies, the researchers fed mice a high-fat diet to induce the development of non-alcoholic fatty liver disease and NASH. They studied these mice for 15 to 18 months to observe the full spectrum of liver disease, including advanced fibrotic changes and liver cancer.   (NEXT)   Half of older adults now die with a dementia diagnosis, up sharply from two decades ago   University of Michigan, April 2, 2022   Nearly half of all older adults now die with a diagnosis of dementia listed on their medical record, up 36% from two decades ago, a new study shows. The study, published in JAMA Health Forum by a University of Michigan team, uses data from 3.5 million people over the age of 67 who died between 2004 and 2017. It focuses on the bills their providers submitted to the traditional Medicare system in the last two years of the patients' lives. In 2004, about 35% of these end-of-life billing claims contained at least one mention of dementia, but by 2017 it had risen to more than 47%. Even when the researchers narrowed it down to the patients who had at least two medical claims mentioning dementia, 39% of the patients qualified, up from 25% in 2004.

Meet Melinda Buntin, Ph.D.:Melinda Buntin, Ph.D is the Mike Curb Professor and Chair of the Department of Health Policy at Vanderbilt University. She is also the deputy editor of JAMA Health Forum. Previously, Dr. Buntin was a Director in the Health, Retirement and Long-Term Analysis Division at the Congressional Budget Office. She also served as chief economist and founding director of the Office of Economics, Evaluation, and Modeling within the Office of the National Coordinator for Health IT. Dr. Buntin received an A.B. from Princeton University and a Ph.D. in Health Policy with a concentration in economics from Harvard.Key Insights:Melinda Buntin, Ph.D. is a leader in health services research and is a health policy expert.Communicating Policy Research. One of Dr. Buntin's goals for her Department of Health Policy is to not only publish high quality research, but also influence policy and give decision makers the data and evidence they need to make good decisions. (15:03)Joining Two Worlds. To improve health policy, policy experts need to have an understanding of how clinics and hospital operate day to day. In turn, healthcare professionals need to understand how they fit into the broader health system. (18:52)Honest Mentorship. A mentor told Dr. Buntin that if she accepted another Federal job, that could close doors to academia in the future. It was hard advice to hear, but she knew it was right, and continued to publish research and maintain ties with former colleagues to keep that option open. (27:28)This episode is hosted by Sanjula Jain, Ph.D. She is a member of the Advisory Council for Her Story, co-founder of Think Medium, and the SVP, Market Strategy and Chief Research Officer at Trilliant Health.Relevant Links:Follow Dr. Buntin on TwitterRead Dr. Buntin's writing for the Commonwealth FundLearn about the JAMA Health Forum

For the duration of the COVID-19 pandemic public health emergency, state Medicaid programs elected to maintain eligibility for Medicaid recipients in exchange for increased federal funding. In this podcast, Dr Laura Dague of the Bush School of Government & Public Service at Texas A&M University discusses her JAMA Health Forum article finding that this policy was associated with the higher Medicaid enrollment seen during the pandemic. JAMA Health Forum Editor John Ayanian and Deputy Editor Melinda Buntin discuss the policy implications of this work with Dr Dague and other recent articles touching on Medicaid enrollment. Related Content: Trends in Medicaid Enrollment and Disenrollment Early in the COVID-19 Pandemic in Wisconsin Medicaid Disenrollment After the COVID-19 Pandemic Medicaid Coverage Disruptions Among Children Enrolled in North Carolina Medicaid, 2016-2018 Association of Medicaid Expansion in Arkansas With Postpartum Coverage, Outpatient Care, and Racial Disparities

For the duration of the COVID-19 pandemic public health emergency, state Medicaid programs elected to maintain eligibility for Medicaid recipients in exchange for increased federal funding. In this podcast, Dr Laura Dague of the Bush School of Government & Public Service at Texas A&M University discusses her JAMA Health Forum article finding that this policy was associated with the higher Medicaid enrollment seen during the pandemic. JAMA Health Forum Editor John Ayanian and Deputy Editor Melinda Buntin discuss the policy implications of this work with Dr Dague and other recent articles touching on Medicaid enrollment. Related Content: Trends in Medicaid Enrollment and Disenrollment Early in the COVID-19 Pandemic in Wisconsin Medicaid Disenrollment After the COVID-19 Pandemic Medicaid Coverage Disruptions Among Children Enrolled in North Carolina Medicaid, 2016-2018 Association of Medicaid Expansion in Arkansas With Postpartum Coverage, Outpatient Care, and Racial Disparities

There are many actors in the drug supply and distribution system, and little is known about the share of drug expenditures going to each, making it more difficult to rein in costs. JAMA Health Forum Associate Editor, Julie Donohue, PhD, and Deputy Editor, Melinda Buntin, PhD, speak with Neeraj Sood, PhD, lead author in a JAMA Health Forum study that unpacks the distribution of insulin expenditures, revealing that a surprising share goes to intermediaries. They also spoke with Bernie Good, MD, who wrote an invited commentary about this study. Related Content: Share of Net Insulin Expenditures Captured in the US Pharmaceutical Distribution System Decomposition of Expenditures for Insulins Across the Distribution Chain—Insights Into Rising Prices?

We know that the pandemic caused millions of people to lose their jobs, and potentially their job-based insurance, and yet new survey data showed surprisingly small changes in uninsurance rates at the end of 2020. Kate Bundorf, PhD, from the Sanford School of Public Policy at Duke University and Jessica Banthin, PhD, of the Urban Institute talk to JAMA Health Forum Deputy Editor Melinda Buntin about these trends and the role played by Medicaid and exchange coverage. JAMA Health Forum Editor John Ayanian and Melinda Buntin also discuss other recent work about health insurance coverage and the ACA that has appeared in JAMA Health Forum. Related Content: Trends in US Health Insurance Coverage During the COVID-19 Pandemic Fewer People May Have Become Uninsured in 2020 Than Feared Outcomes After Changes to US Health Insurance Marketplace Automatic Renewal Rules Income Eligibility for Medicaid vs Marketplace Coverage for Insurance Enrollment Among Low-Income Adults Making the Affordable Care Act Marketplace More Affordable

We know that the pandemic caused millions of people to lose their jobs, and potentially their job-based insurance, and yet new survey data showed surprisingly small changes in uninsurance rates at the end of 2020. Kate Bundorf, PhD, from the Sanford School of Public Policy at Duke University and Jessica Banthin, PhD, of the Urban Institute talk to JAMA Health Forum Deputy Editor Melinda Buntin about these trends and the role played by Medicaid and exchange coverage. JAMA Health Forum Editor John Ayanian and Melinda Buntin also discuss other recent work about health insurance coverage and the ACA that has appeared in JAMA Health Forum. Related Content: Trends in US Health Insurance Coverage During the COVID-19 Pandemic Fewer People May Have Become Uninsured in 2020 Than Feared Outcomes After Changes to US Health Insurance Marketplace Automatic Renewal Rules Income Eligibility for Medicaid vs Marketplace Coverage for Insurance Enrollment Among Low-Income Adults Making the Affordable Care Act Marketplace More Affordable

The COVID-19 pandemic has had far-reaching effects on the use of health care services. Dr Nora Becker of the University of Michigan talks about her research on reductions in the use of women's preventive health services, and JAMA Health Forum Editors Dr John Ayanian and Dr Melinda Buntin discuss other JAMA Health Forum pieces on the effects of state “reopenings” on COVID-19 hospitalizations and deaths, the effects of day care closures on women's participation in the labor force, and news about nursing home outbreaks of COVID-19. Related Content: Utilization of Women's Preventive Health Services During the COVID-19 Pandemic CDC Estimates Thousands of Excess Deaths Among US Patients with End-Stage Renal Disease During COVID-19 Pandemic's Early Months Most US Nursing Homes Had Multiple, Sustained COVID-19 Outbreaks, GAO Reports Association of Childcare Facility Closures With Employment Status of US Women vs Men During the COVID-19 Pandemic US Trends in COVID-19–Associated Hospitalization and Mortality Rates Before and After Reopening Economies Lessons Emerging From COVID-19 Responses by US States

The COVID-19 pandemic has had far-reaching effects on the use of health care services. Dr Nora Becker of the University of Michigan talks about her research on reductions in the use of women's preventive health services, and JAMA Health Forum Editors Dr John Ayanian and Dr Melinda Buntin discuss other JAMA Health Forum pieces on the effects of state “reopenings” on COVID-19 hospitalizations and deaths, the effects of day care closures on women's participation in the labor force, and news about nursing home outbreaks of COVID-19. Related Content: Utilization of Women's Preventive Health Services During the COVID-19 Pandemic CDC Estimates Thousands of Excess Deaths Among US Patients with End-Stage Renal Disease During COVID-19 Pandemic's Early Months Most US Nursing Homes Had Multiple, Sustained COVID-19 Outbreaks, GAO Reports Association of Childcare Facility Closures With Employment Status of US Women vs Men During the COVID-19 Pandemic US Trends in COVID-19–Associated Hospitalization and Mortality Rates Before and After Reopening Economies Lessons Emerging From COVID-19 Responses by US States

A portfolio approach to health care payment reform, where a set number of alternative payment models are selected for testing because they work together to reduce waste, could be a more efficient way to reduce costs and incentivize quality. Michael Chernew, PhD, of Harvard University explains the idea in a conversation with JAMA Health Forum editors John Ayanian, MD, MPP and Melinda Buntin, PhD. Related Content: Alternative Health Care Payment Models—The Case for A Portfolio Strategy

JAMA Health Forum is a peer-reviewed, open access, online journal, focused on health policy, health care systems, and population health.  Our podcast each month presents highlights of new content from the journal, including timely interviews with authors of research studies and commentaries.  Follow us on jamahealthforum.com and jamanetworkaudio.com.

In this pre-pandemic Working People recording that we thought was lost to history, we talk to filmmaker Dominique Rémy about her important full-length documentary on maternal morbidity and mortality rates in Black and Indigenous communities in the U.S.    Additional links/info below... Dominique's Twitter page Maternal Mortality Documentary Film Fund (please donate!) Linda Villarosa, New York Times, "Why America’s Black Mothers and Babies Are in a Life-or-Death Crisis" Amy Roeder, Harvard Public Health, "America Is Failing Its Black Mothers" Elizabeth Chuck, NBC News, "The U.S. Finally Has Better Maternal Mortality Data. Black Mothers Still Fare the Worst" Katy B. Kozhimannil, JAMA Health Forum, "Indigenous Maternal Health—A Crisis Demanding Attention" Elizabeth Chuck & Haimy Assefa, NBC News, "She Hoped to Shine a Light on Maternal Mortality Among Native Americans. Instead, She Became a Statistic of It"   Permanent links below... Working People Patreon page Leave us a voicemail and we might play it on the show! Labor Radio / Podcast Network website, Facebook page, and Twitter page In These Times website, Facebook page, and Twitter page The Real News Network website, YouTube channel, podcast feeds, Facebook page, and Twitter page   Featured Music (all songs sourced from the Free Music Archive: freemusicarchive.org) Jules Taylor, "Working People Theme Song" Evie Sands, "Shine for Me"

JAMA Health Forum editors John Ayanian, MD, MPP, and Melinda Buntin, PhD, discuss changes in US health care and health policy driven by the coronavirus pandemic. Recorded April 16, 2020.